Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853330 | 0.85 | HDAC1 (0.58) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL138449 | 0.85 | GAA (0.68) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL76377 | 0.84 | LMNA (0.59) | ALDH1A1GAALMNAKDM4ETDP1 | |
| SCHEMBL4450255 | 0.84 | ALDH1A1 (0.50) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL2734577 | 0.83 | ABL1 (0.59) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL136681 | 0.83 | HDAC1 (0.60) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL16930166 | 0.82 | HDAC1 (0.56) | HDAC1HDAC6ALDH1A1ABL1RIN1 | |
| SCHEMBL3616256 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GAALMNATDP1SMN1; SMN2 | |
| SCHEMBL3659918 | 0.81 | GAA (0.50) | ALDH1A1ABL1RIN1GAALMNA | |
| SCHEMBL21916970 | 0.81 | HDAC1 (0.54) | HDAC1HDAC6ALDH1A1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-02-13 | — | — | US | disclosed |
| US-8580783-B2 | [1,2,4]triazolo [1,5-c]pyrimidine derivatives as Hsp90 modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L (IT) | 2012-07-19 | — | — | US | disclosed |
| EP-2475665-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029775-A1 | [1,2,4]TRIAZOLO [1,5-c]PYRIMIDINE DERIVATIVES AS Hsup90 MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045836-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | HDAC1 1326/4885HDAC6 110/4885ALDH1A1 1300/4885 |
| US-20120184546-A1 | [1,2,4]TRIAZOLO [1,5-C]PYRIMIDINE DERIVATIVES AS HSP90 MODULATORS | HSP90AB1, HSP90AA1, HSP90AB2P | HDAC1 1242/4885HDAC6 119/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.